(MedPage Today) — Frontline treatment with a CDK4/6 inhibitor did not improve overall survival (OS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer compared with second-line treatment, updated results from a randomized trial…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119981
Author :
Publish date : 2026-02-20 22:12:00
Copyright for syndicated content belongs to the linked Source.
